File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma

TitleA randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma
Authors
KeywordsTherapeutic index
Concurrent-adjuvant chemoradiotherapy
Accelerated fractionation
Nasopharyngeal carcinoma
Issue Date2011
Citation
Radiotherapy and Oncology, 2011, v. 98, n. 1, p. 15-22 How to Cite?
AbstractBackground and purpose: To evaluate the therapeutic benefits by adding chemotherapy (+C) and/or accelerated-fractionation (AF) for patients with T3-4N0-1M0 nasopharyngeal carcinoma. Materials and methods: From 1999 to 2004, 189 eligible patients were randomized to one of four treatment groups (CF/CF + C/AF/AF + C). The number of fractions/week was 5 for the CF groups and 6 for the AF groups. Patients in the +C groups were given concurrent cisplatin plus adjuvant cisplatin and fluorouracil. Results: The AF + C group achieved significantly higher failure-free rate (88% at 5-year) than the CF group (63%; p = 0.013), the AF group (56%; p = 0.001) and the CF + C group (65%; p = 0.027). As compared with CF alone, the increase in late toxicity was statistically insignificant (36% vs. 20%; p = 0.25). Deaths due to cancer progression decreased (7% vs. 33%; p = 0.011) but deaths due to incidental causes increased (9% vs. 2%; p = 0.62). Improvement in overall survival reached borderline significance (85% vs. 66%; p = 0.058). Conclusions: Concurrent-adjuvant chemotherapy combined with AF significantly reduced failure and cancer-specific deaths. Although the increase in major late toxicity and incidental deaths were statistically insignificant, a subtle increase in non-cancer deaths narrowed the overall survival gain. © 2010 Elsevier Ireland Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/213942
ISSN
2015 Impact Factor: 4.817
2015 SCImago Journal Rankings: 2.654

 

DC FieldValueLanguage
dc.contributor.authorLee, Anne W M-
dc.contributor.authorTung, Stewart Y.-
dc.contributor.authorChan, Anthony T C-
dc.contributor.authorChappell, Rick-
dc.contributor.authorFu, Yiu Tung-
dc.contributor.authorLu, Tai Xiang-
dc.contributor.authorTan, Terence-
dc.contributor.authorChua, Daniel T T-
dc.contributor.authorO'Sullivan, Brian-
dc.contributor.authorTung, Raymond-
dc.contributor.authorNg, Wai Tong-
dc.contributor.authorLeung, To Wai-
dc.contributor.authorLeung, Sing Fai-
dc.contributor.authorYau, Stephen-
dc.contributor.authorZhao, Chong-
dc.contributor.authorTan, Eng Huat-
dc.contributor.authorAu, Gordon K H-
dc.contributor.authorSiu, Lillian-
dc.contributor.authorFung, Ka Kit-
dc.contributor.authorLau, Wai Hon-
dc.date.accessioned2015-08-19T13:41:18Z-
dc.date.available2015-08-19T13:41:18Z-
dc.date.issued2011-
dc.identifier.citationRadiotherapy and Oncology, 2011, v. 98, n. 1, p. 15-22-
dc.identifier.issn0167-8140-
dc.identifier.urihttp://hdl.handle.net/10722/213942-
dc.description.abstractBackground and purpose: To evaluate the therapeutic benefits by adding chemotherapy (+C) and/or accelerated-fractionation (AF) for patients with T3-4N0-1M0 nasopharyngeal carcinoma. Materials and methods: From 1999 to 2004, 189 eligible patients were randomized to one of four treatment groups (CF/CF + C/AF/AF + C). The number of fractions/week was 5 for the CF groups and 6 for the AF groups. Patients in the +C groups were given concurrent cisplatin plus adjuvant cisplatin and fluorouracil. Results: The AF + C group achieved significantly higher failure-free rate (88% at 5-year) than the CF group (63%; p = 0.013), the AF group (56%; p = 0.001) and the CF + C group (65%; p = 0.027). As compared with CF alone, the increase in late toxicity was statistically insignificant (36% vs. 20%; p = 0.25). Deaths due to cancer progression decreased (7% vs. 33%; p = 0.011) but deaths due to incidental causes increased (9% vs. 2%; p = 0.62). Improvement in overall survival reached borderline significance (85% vs. 66%; p = 0.058). Conclusions: Concurrent-adjuvant chemotherapy combined with AF significantly reduced failure and cancer-specific deaths. Although the increase in major late toxicity and incidental deaths were statistically insignificant, a subtle increase in non-cancer deaths narrowed the overall survival gain. © 2010 Elsevier Ireland Ltd. All rights reserved.-
dc.languageeng-
dc.relation.ispartofRadiotherapy and Oncology-
dc.subjectTherapeutic index-
dc.subjectConcurrent-adjuvant chemoradiotherapy-
dc.subjectAccelerated fractionation-
dc.subjectNasopharyngeal carcinoma-
dc.titleA randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.radonc.2010.09.023-
dc.identifier.pmid20971520-
dc.identifier.scopuseid_2-s2.0-78651367213-
dc.identifier.hkuros266272-
dc.identifier.volume98-
dc.identifier.issue1-
dc.identifier.spage15-
dc.identifier.epage22-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats